Nyxoah SA (EBR:NYXH)
5.38
-0.24 (-4.27%)
At close: Apr 24, 2025, 5:30 PM CET
Nyxoah Company Description
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA).
The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah SA

Country | Belgium |
Founded | 2009 |
Industry | Medical Instruments & Supplies |
Sector | Healthcare |
Employees | 184 |
CEO | Olivier Taelman |
Contact Details
Address: Rue Edouard Belin 12 Mont-Saint-Guibert, 1435 Belgium | |
Phone | 32 1 022 23 55 |
Website | nyxoah.com |
Stock Details
Ticker Symbol | NYXH |
Exchange | Euronext Brussels |
Fiscal Year | January - December |
Reporting Currency | EUR |
ISIN Number | BE0974358906 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Olivier Taelman | Chief Executive Officer and Executive Director |
Robert Taub MBA | Co-Founder and Chairman |
John Landry | Chief Financial Officer |
Bruno Onkelinx | Chief Technical Officer |
Mikaela Kirkwood | Corporate Communication and Investor Relations Manager |
An Moonen | General Counsel |
Maggie McGowan | Chief Human Resources Officer |
Loic Moreau | President of International |
Remi Renard | Chief of Staff |
Jeyakumar Subbaroyan | Chief Clinical Officer |